STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...
A new tool called SigRM helps researchers study RNA modifications in individual cells, improving our understanding of how genes are regulated. Researchers have developed a new tool that will help ...
RNA plays critical roles in nearly all biological processes, but current methods for sequencing RNA are significantly limited. This is partially because RNA molecules are chemically modified within ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...
CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...
< Photo 1. (From left) Professor Won Do Heo and Jihwan Yu, a Ph.D. Candidate of the Department of Biological Sciences > CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing ...
STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
The innate immune system is the body's first line of defense against pathogens and foreign substances. An essential component of this system are pattern recognition receptors, which recognize non-self ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback